Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Provision of informed consent prior to any study specific procedures
Body mass index (BMI) 19-27 kg/m2 calculated from height and weight at the Screening visit
Clinically normal physical findings including ECG and safety laboratory values at the Screening visit and on Day -1 of each treatment period, including negative results for drugs-of-abuse, alcohol, Hepatitis B, Hepatitis C and HIV.
You may not be if
History of significant mental, cardiac, renal, hepatic or significant gastrointestinal disease (that may affect the rate and extent of absorption of the IP), as judged by the Investigator
Any condition which could modify the absorption of the IPs
Previous randomisation of treatment in the present study
History or symptoms and signs of ongoing severe allergic disease/hypersensitivity
Clareo Health | Bioequivalence Study in Healthy Subjects
